Recursion reports Q3 net loss of $60.4M, initiates two clinical trials; raises $150M private placement

RECURSION PHARMACEUTICALS, INC.

2022-Q3 EPS reported -$1.06 revenue$26,167,000

Cash and cash equivalents $454.6M as of Sept 30, 2022; excludes $150.3M private placement closed Oct 27.
Revenue $13.2M (up from $2.5M YoY) on Roche-Genentech collaboration; net loss $60.4M vs $47.4M YoY.
Initiated Phase 2 TUPELO trial for REC-4881 in FAP and Phase 1 trial for REC-3964 in C. diff colitis.
Nominated REC-4881 for AXIN1/APC mutant cancers; planning Phase 2 trial; deprioritized GM2 gangliosidosis.
R&D expenses $40.8M, G&A $19.5M; both increased due to clinical progress and company growth.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RECURSION PHARMACEUTICALS, INC. reported third quarter September 30, 2022 results: revenue 13.2 million.

Period: third quarter September 30, 2022
Revenue: 13.2 million
Result: reported results

Exact text from the filing

Total revenue, consisting primarily of revenue from collaborative agreements, was $13.2 million for the third quarter of 2022, compared to $2.5 million for the third quarter of 2021.

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001601830-22-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.